NCT05654870View on ClinicalTrials.gov

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

PHASE3TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

November 8, 2023

Study Completion Date

November 8, 2023

Conditions
Schizophrenia
Interventions
DRUG

Valbenazine

Oral treatment

DRUG

Placebo

Placebo matching valbenazine

Trial Locations (3)

30328

Neurocrine Clinical Site, Atlanta

33134

Neurocrine Clinical Site, Coral Gables

95124

Neurocrine Clinical Site, San Jose

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY